AM281 (Synonyms:AM281 抑制剂)
目录号 : KCM12398 CAS No. : 202463-68-1 纯度 : ≥98%
AM281 is a potent and selective central cannabinoid (CB) receptor antagonist/inverse agonist (Ks = 12 nM and 4,200 nM for CB and CB, respectively). Structurally, it is an analog of the CB inverse agonist rimonabant . It has no effect on the vanilloid TRPV1 receptor. AM281 has been used to evaluate the potential effects of compounds at CB It has also been used to study the membrane localization and cycling of CB
规格 价格 是否有货 数量
1mg
In-stock
5mg
In-stock
10mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

AM281 is a selective CB1 receptor antagonist with an IC50 of 9.91 nM. AM281 inhibits CB2 receptor with an IC50 of 13000 nM.

IC50&Target

CB1                                           CB2

9.91 nM (IC50)                          13000 nM (IC50)

体外研究

In the presence of 10 μM KSO 1-6, AM281 (0.01-10 μM) concentration-dependently enhanced the neurotoxicity induced by 10 μM Aβ 25-35 in SH-SY5Y cells.

体内研究

Acute administration of AM281 (2.5, 5, and 10 mg/kg) shortened exploration time and improved memory performance, as did chronic administration of AM281 (0.62, 1.25, and 2.5 mg/kg).
Long term use of 2.5 mg/kg AM281 can increase the recognition index to 22.1, single dose use of 5 mg/kg AM281 can increase memory impairment to 8.5, while carrier treatment can increase it to 4.8. Administration of AM281 at a chronic dose of 2.5 mg/kg and an acute dose of 5 mg/kg can improve memory.

 

Animal Model: Male NMRI mice with the weight of 25-30 g
Dosage: 0.62, 1.25 and 2.5 mg/kg (chronic administration); 2.5, 5 and 10 mg/kg (acute administration)
Administration: Administrated i.p. every day concurrently with morphine except the day of experiment (chronic administration); Singly injected 40 min before second trial (acute administration)
Result: The simultaneous daily administration of AM281 with morphine significantly shortened the exploration time, as compared with morphine-dependent mice receiving vehicle.
Acute administration at a dose of 5 mg/kg, significantly augmented recognition index.
 
分子式
C21H19Cl2In4O2
分子量
557.21
CAS号
202463-68-1
中文名称
1-(2,4-二氯苯)-5-(4-碘苯基)-4-甲基-N-4-吗啉基-1H-吡唑-3-甲酰胺;1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-4-吗啉基-1H-吡唑-3-甲酰胺;1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-4-吗啉基-1H-吡唑-3-羧胺;1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-吗啉-1H-吡唑-3-甲酰胺;4-戊基溴锌;
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
溶解性数据
In Vitro:

DMSO : 7.14 mg/mL (12.81 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7947 mL 8.9733 mL 17.946 mL
5 mM 0.3589 mL 1.7947 mL 3.5893 mL
10 mM 0.1795 mL 0.8973 mL 1.7947 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO → 90% corn oil

    Solubility: ≥ 0.71 mg/mL (1.27 mM); Clear solution

    此方案可获得 ≥ 0.71 mg/mL (1.27 mM,饱和度未知) 的澄清溶液,此⽅案不适⽤于实验周期在半个⽉以上的实验。

    以 1 mL 工作液为例,取 100 μL 7.1 mg/mL 的澄清 DMSO 储备液加到 900 μL ⽟⽶油中,混合均匀。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积:

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。